Infectious Disease Research Institute (IDRI), US, a not-for-profit organization, applies innovation to the R&D of products to prevent, detect and treat infectious diseases. IDRI's research efforts include vaccine discovery, drug discovery and diagnostics.

Novartis Institute for Tropical Diseases, Singapore, established in 2003, is a public-private partnership between Novartis and the Singapore Economic Development Board (EDB), which is developing novel therapies for MDR TB through genomics, bioinformatics and drug discovery technologies.

Private companies

GlaxoSmithKline's Tres Cantos Medicines Development Campus, Spain, works with several organisations, including Global Alliance for TB Drug Development (TB Alliance), to develop effective TB drugs.

AstraZeneca, India, which established its R&D in Bangalore more than 20 years ago, opened a dedicated tuberculosis research centre in 2003. The centre receives funding worth $5 million each year and employs over 80 scientists, who have access to all AstraZeneca's technologies including high throughput screening and compound libraries.